Business
Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 4, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its financial results for the three-month and nine-month periods ended September 30, 2025, and provided a corporate update. “We continue to make great progress with our GABAB positive allosteric modulator (PA
About this update from Addex Therapeutics Ltd
[{"type":"image","alt":"Addex Therapeutics","displaySize":"","headline":null,"caption":"Addex Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":231,"height":115,"url":"https://media.zenfs.com/en/globenewswire.com/1f8146359a7fe2dec0ebef0293b159e7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/i1_J.LrQ5M.Eo1NBP2WLjA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIwOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/1f8146359a7fe2dec0ebef0293b159e7","width":231,"height":115}},"lazy":false},{"type":"text","content":"Ad Hoc Announcement Pursuant to Art. 53 LR","length":42,"tagName":"p"},{"type":"text","content":"Geneva, Switzerland, December 4, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its financial results for the three-month and nine-month periods ended September 30, 2025, and provided a corporate update.","length":372,"tagName":"p"},{"type":"text","content":"“We continue to make great progress with our GABAB positive allosteric modulator (PAM) candidate in chronic cough following demonstration of robust anti-tussive activity in multiple chronic cough preclinical models earlier in the year as well as advancing dipraglurant for post-stroke recovery,” said Tim Dyer, CEO of Addex.","length":324,"tagName":"p"},{"type":"text","content":"Operating Highlights:","length":21,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Continued advancing GABAB PAM chronic cough candidate through preclinical development","length":85,"tagName":"p"}]},{"val":[{"type":"text","content":"Advancing the preparation of dipraglurant for clinical studies in post-stroke recovery","length":86,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":171,"olType":false},{"type":"text","content":"Key Q3 2025 Financial Data","length":26,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"style":"width:283.87px;border-bottom:solid black 1pt;vertical-align:bottom;","val":[{"type":"text","content":"CHF’ thousands","length":14,"tagName":"p","attribs":{}}]},{"style":"width:66.14px;text-align:center;vertical-align:middle;border-bottom:solid black 1pt;vertical-align:bottom;","val":[{"type":"text","content":"Q3 25","length":5,"tagName":"p","attribs":{}}...